Good afternoon. fiscal QX Thank our you, And to XXXX call. welcome year earnings Christina.
our President Sims. said Marc Hedrick, Chief CEO Christina Officer, is I’m and Mr. Andrew Plus Therapeutics. of As Financial And me joining
on this pleased am you families and team, fiscal of the us Once of quarter first best drags your as year I results pandemic all on. that XXXX. of on very possible we hoping again, to Plus behalf report health from are the the are maintaining Therapeutics Today
I Before results, QX it to to like to the our situation update applies Plus. and you as I COVID-XX update get on would
well substantially strategic implement XXXX to serving pandemic. operating the a decision is model us Our during virtual
and XXXX steps Texas and with to company moving of have Our has Governor as schedules as staffed the implemented with to towards health been mode Abbott's business to remained operational order facilities flexible to Plus recommended in employees San soon Coincident put reopening open, return intended executive Austin mode on the work federal our All full a full plan a on the while to for provide trajectory have intended implemented. protect Antonio but possible. operational XX, state April employees. lightly Phase maximum X effective support
change. expect material we fiscal At ends the occurred, our Over the not interruptions supply of results none our situation to partners, this December tested vendors ensure three close positive and two year months no XXXX. to with significant impact in we does employees which XX, remain have currently on have no XXXX chain past point, coordination and for
We ongoing from to we hospital some precautions our more see for and operations. screen continue clinical to starting away COVID are routine shifts to patients trial
to in efforts clinical We also continue our add trial new progress make to sites.
the and Relatedly, bank program in we provisions approval loan. CARES explored a PPP PPP the modest passed and of fact law received the for recently
that at that and However, we relatively proactively normal company determine to in was in the participate it program work quarter, appropriate execute as that has to fashion a public a not past the continued time. for this
final point a lion's doctors, such as with workforce, practitioners nurses by patients, healthcare besides As personal the affected share masks, PPE the COVID-XX issue this our donated to in protective our equipment of regard for and including QX, caring other we those frontline inventory protecting gloves, to pandemic.
situation no are we supply equipment to changed, impact. now able the has As adverse that corporate replace with
that forward. more brain day public these that as this just of investment may a but the issuer. generally our think We than one view more of to closing redefining of we pipeline, and cancers, quarter While but additions met other assets believe other redefine certainly candidates beyond Monday we values announced portfolio we and prospect we should We hold Therapeutics cancer added the business brain indications. treat this strongly first as the of have a drug was whole the this the the and way our Relatedly, many pipeline to our and of the announcement a addition way cancer the illustrative is themselves, going significant this and a cancer the recent way scientific company treat transaction shareholders transaction. highlight poorly Plus
candidates voting company Texas U.S. payments European review $XXX,XXX up from single-digit of included product the the After based Therapeutics. transaction cancer and a million cash and company, royalty NanoTx biotechnology transaction Plus in payment may we the $XXX,XXX itself, upfront The and brief stock. in rare private an drug and in licensed Furthermore, terms tiered sales. and development on pay to sales milestone $XXX.X multiple
called The asset chelated glioblastoma rhenium nanoliposome, is brain lead in-licensed drug being cancer. and recurrent or developed also which is RNL for
as a some inside-out radiation the in While drug. implants fashion that RNL for an rather in the ways which case is similar external than differs, though, with beam in the delivered is delivered radiation. by radiation in as brachytherapy is is the outside-in It to radiation
liquid advantages over approach radiotherapy. called is and confers this traditional external brachytherapy approach more our In versatile some and fact, both brachytherapy. But importantly, technical have many beam
all on Later cancers call, executed put This first therapeutics background rebranding, pipeline radio with XXXX perspective. like and of to more the and I'll long-term core to cost the our some XXXX strategic licensed rebuilding durable more for involve This key transaction key and provided in I'd But development the Plus company transaction financial innovative enhances these diseases. provide structure viability corporate a geographic company put pipeline and but in only strength, the relocation. place successfully rare company and and be stage reformation, Ultimately, positions the team, critical newly a operating corporate functions clinical the chemotherapeutics pharmaceuticals. technology. in other putting our moves In possible not transactions, to XXXX significant expands transition to Therapeutic for on developing transition where in leadership a necessary growth. nanotechnology, virtualizing financial path the focus our elements platform
stated development of our and to achieve and novel expansion expertise while model, sources transaction of. This focus We a met more we quarters, cost non-dilutive inherently drug poorly specifically indications, closure formulation and leveraging excited finally, this the strategic publicly our worked nanoliposomes. more announced clinical drug mentioned we via on in aims is first virtual the three of are efficient licensing consistent leveraging with strategic transaction pipeline, funding, hard in our development oncology timeframe rare, this and just that equally about transition frequently over that last
that as we prefer Also, three previously drug criteria. plan, in meet candidates key invest our noted in we to
an unmet or First, need. medical they underserved address substantially
combine Second, pharmaceutical boxes. safety safety annual three at prefer both information active transaction most efficacy. have a The this improve and check million new addressable basis. third, efficacy that extensive and that they $XXX technologies known opportunity drug an least we ingredients have And that recent RNL in they candidates on all market with
newly treatments As nanoliposome being potentially initially nanoliposome-encapsulated mentioned asset treat the of chelated a and license related targets RNL good technologies, is portfolio The lead of rhenium cancer useful consists above, drug essentially have key radionucleotides that today. Cancer by a don't to developed number the consortium esteemed drug Antonio, multi-institutional glioblastoma. the in It developed led by The RNL UT Andrew licensed MD Anderson based Mays for Center, was platform neuro-oncologist, Dr. and was Centers. San recurrent Cancer Health a at Texas Brenner.
enhanced and times directly brain initial allows therapeutic as and brain radiation and has the in that's radiation the that precision normal chemo much tissue glioblastoma, patients typical of structures dose and blast a recurred to as to damage external of and case tissues, the is unlike whose treatment beam normal technology radiation convection delivery into the XX affects typical terms the of infused via delivery the colloquial radiation the surgical collateral radiation. directly very surrounding resection high and rifle of a targeting following high caliber target of cancer head, mapping precision is to with tumor is the tumor of the shot shotgun tumor. other RNL of that that doses of brain It's only in tumor RNL neck, plus In face.
delivered once number it shot after of achieve has that cumulative other standard a technical is that Furthermore, weeks unlike tumors. over beam More tolerated scientifically, dose. radiation order to features rifle a it's day, delivered potentially and for single to other day glioblastoma RNL approaches give advantages external in a
imaging as particle beta any First, it also delivers a half in and cancer radiation external Rhenium-XXX purposes, imaging or very with where on high after help emits a reach to a residual that micro XX is Three, radio millimeters marrow, delivered. for tumor. another but gamma thyroid made X damage tumor collateral isotope in bone life of Specificity dual brain hours time EBRT know the to It's to metabolized electron the particle free a it's lead to dividing organs I has doctors kidneys kill or times increase beyond up precision rhenium’s to as energy local or the long it and the nuclear radiation delivered without directly energy safely has the each approximately person beam such novel time doses I-XXX very cancer, Six, emitter. with imaging glioblastoma. high radiation, rapidly technologies. both to and X for a delivery the perhaps reactor it’s of beta Two, are mentioned indications is or at it treatment. specificity. structures for similar sensitive by non-enhancing cells atom fields that to barrier so blood delivered XX tumor Five, tumor
regime most an and today, year EBRT colleagues and approved people may compared tumor of notably, U.S. of with for survival treating Even survival currently effective chemotherapy And treatment. that an show technology have concept the standard patented or there the to all radiation marginal treatments the only therapeutic benefit. X.X this the months for Multiple in glioblastoma, developed per EBRT which aggregate month his prolong initial affects after fields. Dr. with the using XX,XXX Brenner that with in glioblastoma recur in a and survival today. about months it recurrent in tumors improvement primary radiation studies few And a randomized with provide therapy three additional five addition patients multimodal component that essentially cancer is are
into directly action and are By external radiation adequate energy of against unambiguous. electrons effective the the RNL tissues of brain mechanism infusing is in drugs from effectively In delivered. the the the bypassing the damage. normal know high dose brain can radiation an be if case of tumor, these form barrier, spared We glioblastoma, drug is blood
gray. radiation a most in recurrent dosed gray. with about recent glioblastoma typically For RNL comparison, max patient external contrast current protocols over clinical to for XXX total of trial our dose recommend beam received XX In
in with two the are at coverage XX a subsequent X terms thus Texas and Anderson observed to the far. are been single events escalation sites dose radiation typically a at in Though specifically to study with approximately beam compared about that's Antonio, for MD underway in FDA doses cohorts XX tumor cohort. significant Phase respectively. dose efficacy, San UT to to we fifth nine survival clinical is months have current powered which median the the first and establish we external expand additional now of XX RNL was no In UT are now finding cohort That two Thus or trial far, approved current is currently planned received patients the in in U.S. status, standard-of-care. Texas is volumes Higher dose to in times achieved, dosing radiation. not months The Houston. in actions delivered intended site in that and in serious patients, adverse survived and of who for six by Southwestern
Additionally, and Institutes Cancer Prevention the was the of of Phase technology Institute. substantial review National in National support. funding and has previously and by It Cancer its the currently, trial is funded Texas; party Research the granted through technology Institute addition, Health/ third X by
RNL cancers. way for glioblastoma, as get be breast to the a expect development in candidate, that game on and information of Even indications super ability QX high about the prior enthusiastic because indications website. our on Beyond carcinomatosis head, the RNL high product energy QX use the to Please leptomeningeal, changer what active began these published on and team clinical data I refer these more available it ovarian company. Also, and liver analysis The on very exact same this of cancer, for already doses precisely in close transaction, the there's of indications this much referenced tumor-only technology. tough and beyond problems. more this is to including technology and for a from or and additional the additional works radiation in follow several neck of call could can preclinical our same some we of the to for deliver
trial. glioblastoma, for a enrollment for applicability Phase trial working as program, even pipeline are will the Regarding a also FDA pivotal the X in And for next preparations the for follow besides begin appropriate accelerated steps we the to RNL and track orphan globally. complete we Phase on X designations in designations fast advancing U.S. we determine
only development DoxoPLUS, and further Regarding DocePLUS assets currently their our other plan to partner support. stage with two we clinical
We its on are are we discussions and have been but development. at and in resources present such RNL focusing
of our other a continue pipeline. to expand in-licensing opportunities to review we co-development and Additionally, number
let's So of the to over turn with review a comments, quarter. those Andrew call the for Andrew?
